Loading news...
Bamco Inc. NY grew its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 3,071.3% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,268,532 shares of the company's stock after acquiring an additional 1,228,532 shares during the period. Bamco Inc. NY owned about
ARS Pharmaceuticals, Inc. maintains a Hold rating as neffy's commercial uptake remains slow despite FDA approval and a robust marketing push. SPRY reported 2025 revenues of $84.3m, a net loss of $171.3m, and plans to sustain high SG&A spending to accelerate U.S. market share. Management offers no 2026 revenue guidance, raising concerns about breakeven prospects and ongoing competition from established and emerging epinephrine products.
ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.52 per share a year ago.
neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0 million in cash, cash equivalents and short-term investments supports operating plan through anticipated cash-flow break-even Conference call to be held today, March 9, 2026, at 5:30 a.m. PT / 8:30 a.m.
ARS Pharmaceuticals, Inc. (SPRY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m.
Krystal Biotech pioneered the first topical gene therapy. ARS Pharmaceuticals introduced the first needle-free therapy to treat anaphylaxis.
SPRY's main product is Neffy, which is a needle-free epinephrine spray. Its sales are ramping quickly, and Q3 2025 sales hit $31.3 million. My core thesis is that Neffy's more convenient delivery mechanism will resonate with patients far better than injections. Also, a convenient nasal spray is a much simpler administration method that should reduce user error and unlock diagnosed-but-untreated anaphylaxis demographics.
-Five poster presentations highlight clinical advancement of neffy , real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients' dislike of needle-based administration, the value of a nasal option increased by more than 25% SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five poster presentations, one healthcare professional (HCP) case report, plus two late breakers from partners at ALK-Abelló A/S (ALK) centered on neffy , will be featured at the 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting, February 27 to March 2, 2026 in Philadelphia, Pennsylvania. The posters highlight health-economic analyses, patient preference research, usability and pharmacokinetic comparisons evaluating neffy relative to injectable epinephrine products.
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending expanding the marketing authorization for EUR neffy ® to include a 1 mg nasal adrenaline spray. EUR neffy 1 mg is for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis, in children who weigh ≥15 kg and
Campbell and CO Investment Adviser LLC purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 60,525 shares of the company's stock, valued at approximately
California joins 23 other states eligible to receive free neffy ® (epinephrine nasal spray) at schools SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that California, the state where ARS Pharma is headquartered, is now eligible for its neffy inSchools program. Type 1 allergic reactions, including anaphylaxis, can happen quickly and be caused by foods, insects, medication, exercise, or other unknown causes and can only be treated with epinephrine.
FAS Wealth Partners Inc. increased its stake in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 34.5% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 200,620 shares of the company's stock after purchasing an additional 51,460 shares during the quarter. FAS Wealth Partners
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) stock rose Friday in reaction to a negative update for its rival Aquestive Therapeutics Inc. (NASDAQ: AQST).
Shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the eight analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have given a buy rating
neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( > 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速 ® , expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced that the National Medical Products Administration (NMPA) in China has granted approval for neffy 2 mg (epinephrine nasal spray) for the emergency treatment of Type 1 allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more. In China, the trade name is 优敏速 ® meaning “Excellent Allergy (treatment) Fast”.
Permanent Capital Management LP purchased a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 53,341 shares of the company's stock, valued at approximately $536,000. Permanent Capital Management
Ardsley Advisory Partners LP raised its holdings in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 46.2% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 475,000 shares of the company's stock after purchasing an additional 150,000 shares during the period.
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and ARS Pharmaceuticals (NASDAQ: SPRY - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Analyst Recommendations This is a breakdown of